Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease
Recruiting now · Phase 2
Conditions studied: Rosai-Dorfman Disease
In brief
In patients with Rosai-Dorfman disease (RDD), a treatment regimen of lenalidomide combined with dexamethasone is planned to be used.
Key facts
- Study ID
- NCT07187167
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- People needed
- 40
- Starts
- 2025-04-12
- Expected to finish
- 2027-04-12
- Last updated by the study team
- 2025-09-22
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Definitively diagnosed adult RDD patients;
- Aged between 18 and 80 years;
- Treatment-naive or refractory/relapsed;
- ECOG performance status score ≤ 2;
- Judged by clinicians as suitable for treatment with this protocol;
- Patients or their families able to understand the study protocol and willing to participate in the study, providing written informed consent.
You may not qualify if…
- Subjects who have undergone major surgery within 4 weeks prior to the first dose of the study;
- Subjects who have received radiotherapy within 4 weeks prior to the first dose of the study;
- Subjects with a history of myocardial infarction within the past year;
- Patients with New York Heart Association (NYHA) Class 3 or 4 congestive heart failure, or a history of NYHA Class 3 or 4 congestive heart failure;
- Pregnant or lactating women;
- Patients who cannot strictly practice contraception after participating in the study;
- Abnormal liver and kidney function: creatinine level ≥176.8 μmol/L (2 mg/dL), transaminase and bilirubin levels more than 2 times the upper limit of normal
- Abnormal blood counts: absolute neutrophil count less than 1×10\^9/L, platelet count less than 50×10\^9/L;
- Patients or their families who cannot understand the conditions and objectives of the study;
- Any other situation where the investigator considers the patient unsuitable to participate in this trial.
Where it is running
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.